Form 8-K - Current report:
SEC Accession No. 0001641172-25-016002
Filing Date
2025-06-23
Accepted
2025-06-23 07:45:39
Documents
16
Period of Report
2025-06-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 73725
2 EX-2.1 ex2-1.htm EX-2.1 883090
3 EX-10.1 ex10-1.htm EX-10.1 99553
4 EX-10.2 ex10-2.htm EX-10.2 78116
5 EX-99.1 ex99-1.htm EX-99.1 32452
  Complete submission text file 0001641172-25-016002.txt   1526308

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ibo-20250623.xsd EX-101.SCH 3032
7 XBRL LABEL FILE ibo-20250623_lab.xml EX-101.LAB 34239
8 XBRL PRESENTATION FILE ibo-20250623_pre.xml EX-101.PRE 22371
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3848
Mailing Address 1400 BROADFIELD BLVD. SUITE 130 HOUSTON TX 77084
Business Address 1400 BROADFIELD BLVD. SUITE 130 HOUSTON TX 77084 585 232 1500
IMPACT BIOMEDICAL INC. (Filer) CIK: 0001834105 (see all company filings)

EIN.: 853926944 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42212 | Film No.: 251062979
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)